- 現金殖利率: 3.31%、總殖利率: 3.31%、5年平均現金配發率: 117.86%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 2.21 | 52.41 | 2.00 | 11.11 | 0.00 | 0 | 90.50 | -27.1 | 0.00 | 0 | 90.50 | -27.1 |
| 2024 (4) | 1.45 | 61.11 | 1.80 | 20.0 | 0.00 | 0 | 124.14 | -25.52 | 0.00 | 0 | 124.14 | -25.52 |
| 2023 (3) | 0.90 | -57.55 | 1.50 | -25.0 | 0.00 | 0 | 166.67 | 76.67 | 0.00 | 0 | 166.67 | 76.67 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 0.60 | 5.26 | 81.82 | 0.64 | 14.29 | 82.86 | 0.60 | -72.97 | 81.82 |
| 25Q4 (7) | 0.57 | -35.23 | 50.0 | 0.56 | -30.86 | 47.37 | 2.22 | 34.55 | 53.1 |
| 25Q3 (6) | 0.88 | 100.0 | 175.0 | 0.81 | 24.62 | 97.56 | 1.65 | 114.29 | 54.21 |
| 25Q2 (5) | 0.44 | 33.33 | 91.3 | 0.65 | 85.71 | 195.45 | 0.77 | 133.33 | 2.67 |
| 25Q1 (4) | 0.33 | -13.16 | 0.0 | 0.35 | -7.89 | 0.0 | 0.33 | -77.24 | 0.0 |
| 24Q4 (3) | 0.38 | 18.75 | 0.0 | 0.38 | -7.32 | 0.0 | 1.45 | 35.51 | 0.0 |
| 24Q3 (2) | 0.32 | 39.13 | 0.0 | 0.41 | 86.36 | 0.0 | 1.07 | 42.67 | 0.0 |
| 24Q2 (1) | 0.23 | 0.0 | 0.0 | 0.22 | 0.0 | 0.0 | 0.75 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 1.45 | -3.47 | 6.98 | 6.64 | 7.65 | 5.27 | N/A | - | ||
| 2026/3 | 1.5 | -35.6 | 17.12 | 5.19 | 7.84 | 5.19 | 1.08 | - | ||
| 2026/2 | 2.33 | 70.09 | -4.46 | 3.69 | 4.48 | 5.49 | 1.02 | - | ||
| 2026/1 | 1.37 | -23.98 | 24.27 | 1.37 | 24.27 | 5.49 | 1.03 | - | ||
| 2025/12 | 1.8 | -22.55 | 14.88 | 20.63 | 1.66 | 5.46 | 1.04 | - | ||
| 2025/11 | 2.32 | 73.65 | -1.33 | 18.83 | 0.55 | 5.02 | 1.13 | - | ||
| 2025/10 | 1.34 | -1.43 | 2.62 | 16.51 | 0.82 | 5.21 | 1.09 | - | ||
| 2025/9 | 1.36 | -45.97 | 3.65 | 15.17 | 0.67 | 5.32 | 1.06 | - | ||
| 2025/8 | 2.51 | 73.45 | 4.55 | 13.81 | 0.38 | 5.34 | 1.05 | - | ||
| 2025/7 | 1.45 | 4.82 | -4.83 | 11.3 | -0.49 | 5.13 | 1.09 | - | ||
| 2025/6 | 1.38 | -40.0 | 9.95 | 9.85 | 0.17 | 5.04 | 1.09 | - | ||
| 2025/5 | 2.3 | 70.41 | -1.6 | 8.47 | -1.25 | 4.93 | 1.11 | - | ||
| 2025/4 | 1.35 | 5.67 | 8.8 | 6.17 | -1.12 | 5.07 | 1.08 | - | ||
| 2025/3 | 1.28 | -47.47 | 4.66 | 4.82 | -3.59 | 4.82 | 1.12 | - | ||
| 2025/2 | 2.44 | 121.24 | 6.8 | 3.54 | -6.26 | 5.1 | 1.06 | - | ||
| 2025/1 | 1.1 | -29.73 | -26.24 | 1.1 | -26.24 | 5.02 | 1.08 | - | ||
| 2024/12 | 1.57 | -33.48 | 13.89 | 20.3 | 7.85 | 5.23 | 1.01 | - | ||
| 2024/11 | 2.36 | 80.61 | -5.78 | 18.73 | 7.37 | 4.97 | 1.06 | - | ||
| 2024/10 | 1.3 | -0.44 | -7.62 | 16.37 | 9.57 | 5.02 | 1.05 | - | ||
| 2024/9 | 1.31 | -45.5 | 13.22 | 15.07 | 11.37 | 5.24 | 1.03 | - | ||
| 2024/8 | 2.4 | 57.87 | -1.5 | 13.76 | 11.19 | 5.18 | 1.04 | - | ||
| 2024/7 | 1.52 | 21.11 | 32.48 | 11.36 | 14.32 | 5.12 | 1.05 | - | ||
| 2024/6 | 1.26 | -46.31 | -0.06 | 9.84 | 11.94 | 4.84 | 1.1 | - | ||
| 2024/5 | 2.34 | 88.44 | 3.9 | 8.58 | 13.95 | 4.81 | 1.11 | - | ||
| 2024/4 | 1.24 | 1.65 | 4.44 | 6.24 | 18.24 | 4.74 | 1.12 | - | ||
| 2024/3 | 1.22 | -46.39 | 1.52 | 4.99 | 22.26 | 4.99 | N/A | - | ||
| 2024/2 | 2.28 | 52.77 | 15.08 | 3.77 | 30.93 | 5.15 | N/A | - | ||
| 2024/1 | 1.49 | 8.51 | 65.8 | 1.49 | 65.8 | 5.37 | N/A | 主要係去年1月春節假期9天,實際工作天少;另逢1月流感季節，客戶對本公司產品需求大增，致合併營收較去年同期增加。 | ||
| 2023/12 | 1.38 | -44.97 | 5.44 | 18.82 | -21.54 | 5.29 | N/A | - | ||
| 2023/11 | 2.5 | 77.09 | 10.79 | 17.44 | -23.09 | 5.07 | N/A | - | ||
| 2023/10 | 1.41 | 22.03 | 26.39 | 14.94 | -26.84 | 5.01 | N/A | - | ||
| 2023/9 | 1.16 | -52.6 | -26.23 | 13.53 | -29.91 | 4.75 | N/A | - | ||
| 2023/8 | 2.44 | 112.36 | -29.36 | 12.38 | -30.24 | 4.85 | N/A | - | ||
| 2023/7 | 1.15 | -8.64 | -27.86 | 9.94 | -30.45 | 4.66 | N/A | - | ||
| 2023/6 | 1.26 | -44.18 | -48.17 | 8.79 | -30.78 | 4.7 | N/A | - | ||
| 2023/5 | 2.25 | 89.42 | -41.99 | 7.53 | -26.67 | 4.65 | N/A | - | ||
| 2023/4 | 1.19 | -1.18 | -35.22 | 5.27 | -17.34 | 4.37 | N/A | - | ||
| 2023/3 | 1.2 | -39.23 | -14.13 | 4.09 | -10.12 | 4.09 | N/A | - | ||
| 2023/2 | 1.98 | 120.1 | 1.76 | 2.88 | -8.33 | 4.19 | N/A | - | ||
| 2023/1 | 0.9 | -30.98 | -24.77 | 0.9 | -24.77 | 4.46 | N/A | - | ||
| 2022/12 | 1.3 | -42.18 | -6.56 | 23.99 | 26.16 | 4.68 | N/A | - | ||
| 2022/11 | 2.26 | 102.02 | 7.44 | 22.68 | 28.75 | 4.94 | N/A | - | ||
| 2022/10 | 1.12 | -28.77 | -2.88 | 20.43 | 31.64 | 6.14 | N/A | - | ||
| 2022/9 | 1.57 | -54.61 | 11.33 | 19.31 | 34.4 | 6.62 | N/A | - | ||
| 2022/8 | 3.45 | 116.88 | 58.77 | 17.74 | 36.91 | 7.47 | N/A | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/7 | 1.59 | -34.36 | -6.81 | 14.29 | 32.5 | 7.9 | N/A | - | ||
| 2022/6 | 2.43 | -37.52 | 35.11 | 12.69 | 39.91 | 8.15 | N/A | - | ||
| 2022/5 | 3.88 | 111.51 | 52.78 | 10.27 | 41.09 | 7.12 | N/A | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/4 | 1.84 | 30.98 | 84.86 | 6.38 | 34.81 | 5.19 | N/A | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/3 | 1.4 | -27.98 | 26.68 | 4.55 | 21.52 | 4.55 | N/A | - | ||
| 2022/2 | 1.95 | 62.69 | 15.26 | 3.14 | 19.35 | 4.54 | N/A | - | ||
| 2022/1 | 1.2 | -14.27 | 26.67 | 1.2 | 26.67 | 4.69 | N/A | - | ||
| 2021/12 | 1.4 | -33.52 | -18.89 | 19.01 | 21.2 | 4.65 | N/A | - | ||
| 2021/11 | 2.1 | 82.6 | -1.85 | 17.62 | 26.14 | 4.66 | N/A | - | ||
| 2021/10 | 1.15 | -18.34 | -0.1 | 15.52 | 31.2 | 4.73 | N/A | - | ||
| 2021/9 | 1.41 | -35.27 | 9.04 | 14.37 | 34.58 | 5.29 | N/A | - | ||
| 2021/8 | 2.18 | 27.29 | 31.07 | 12.96 | 38.1 | 5.68 | N/A | - | ||
| 2021/7 | 1.71 | -4.83 | 66.01 | 10.78 | 39.61 | 6.05 | N/A | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，及新併入之子公司營收，致整體營收增加。 | ||
| 2021/6 | 1.8 | -29.34 | 125.5 | 9.07 | 35.54 | 0.0 | N/A | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 | ||
| 2021/5 | 2.54 | 155.92 | 67.32 | 7.28 | 23.39 | 0.0 | N/A | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 |